US 12,447,206 B2
Nanoparticle vaccines with novel structural components
Linling He, San Diego, CA (US); and Jiang Zhu, San Diego, CA (US)
Assigned to The Scripps Research Institute, La Jolla, CA (US)
Filed by The Scripps Research Institute, La Jolla, CA (US)
Filed on Jul. 27, 2021, as Appl. No. 17/386,289.
Application 17/386,289 is a division of application No. 16/440,067, filed on Jun. 13, 2019, granted, now 11,097,002.
Claims priority of provisional application 62/684,229, filed on Jun. 13, 2018.
Prior Publication US 2022/0031835 A1, Feb. 3, 2022
Int. Cl. C07H 21/02 (2006.01); A61K 39/21 (2006.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61P 31/18 (2006.01); C12N 15/86 (2006.01); B82Y 5/00 (2011.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01)
CPC A61K 39/21 (2013.01) [A61K 47/6425 (2017.08); A61K 47/6929 (2017.08); A61P 31/18 (2018.01); C12N 15/86 (2013.01); B82Y 5/00 (2013.01); B82Y 30/00 (2013.01); B82Y 40/00 (2013.01)] 35 Claims
OG exemplary drawing
 
1. A polynucleotide, encoding a fusion protein comprising (a) an polypeptide immunogen, (b) a self-assembling nanoparticle subunit, and (c) a locking domain subunit that comprises the amino acid sequence set forth in SEQ ID NO:2, or a conservatively modified variant thereof.